Aclaris Therapeutics ACRS Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's retained earnings?
- Aclaris Therapeutics (ACRS) reported retained earnings of -$987.61M in Q1 2026.
- How has Aclaris Therapeutics's retained earnings changed year-over-year?
- Aclaris Therapeutics's retained earnings decreased by 7.6% year-over-year, from -$917.95M to -$987.61M.
- What is the long-term trend for Aclaris Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Aclaris Therapeutics's retained earnings has grown at a 13.9% compound annual growth rate (CAGR), from -$504.54M to -$967.78M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.